Santen Hosts Event to Raise Public Awareness of Importance of Continued Glaucoma Treatment Prior to Sponsoring World Glaucoma Week in March

Food and Healthcare Press Releases Wednesday January 30, 2019 13:00
OSAKA, Japan--30 Jan--Kyodo JBN-AsiaNet/InfoQuest

As part of its efforts to raise public awareness of glaucoma, Santen Pharmaceutical Co., Ltd. (hereinafter "Santen"), based in Osaka, will sponsor glaucoma awareness-raising activities to be conducted around the world during the World Glaucoma Week, from Sunday, March 10, to Saturday, March 16, 2019.

Glaucoma is an eye disease that causes damage to the optic nerve, resulting in progressive visual field loss. Although this disease can lead to loss of vision when left untreated, early treatment often allows patients to maintain visual field throughout their lifetime. Therefore, early detection through regular ophthalmic consultation is the desirable starting point when treating glaucoma. The World Glaucoma Association, of which Santen is an Associate Glaucoma Industry Member, defines one week every March as the World Glaucoma Week and hosts various events and awareness-raising activities around the world to encourage people to detect and begin treating glaucoma as early as possible.

Santen has also implemented various initiatives to increase public awareness of the importance of early detection and continued treatment of glaucoma. As part of such initiatives, Santen hosted the disease awareness-raising event "Recommendations for Continued Treatment and Care" targeting glaucoma patients in Nagoya, Aichi Prefecture, central Japan, on November 17, 2018. This event included a makeup lesson given by facial therapist Ms. Reiko Kazki (hereafter "Ms. Kazki"), a pioneer in rehabilitation makeup*, and a lecture by glaucoma specialist Dr. Aiko Iwase (Director of Tajimi Iwase Eye Clinic, hereafter "Dr. Iwase").


Although many types of eye drops are available for treating glaucoma, they can sometimes bring about adverse effects, such as hyperpigmentation (abnormal coloring) around the eyes and deepening of the upper eyelid sulcus (sunken eyes).

An important challenge of glaucoma treatment is that some patients hesitate to receive continued treatment out of concern about such side effects or stop using eye drops based on their own judgment. This event was held to provide such patients with the opportunity to overcome their feelings about the adverse effects and increase their awareness of the importance of continued treatment.

At the event venue, Ms. Kazki's demonstration of rehabilitation makeup* aimed at making the adverse effects of eye drops for glaucoma inconspicuous met with cries of surprise from both female and male audience members. Ms. Kazki also gave a hands-on makeup lesson to some in the audience. Dr. Iwase explained in her lecture, "Continued glaucoma treatment allows patients to maintain vision field. Drug side effects sometimes inevitably accompany glaucoma treatment, and discourage some patients to continue receiving treatment. My strong desire to change this situation motivated me to participate in this event."

Santen also continues to regard the World Glaucoma Week as a period for employees to learn about glaucoma on their own initiative and impart their learning to their loved ones, including family members and friends. The company will devote further efforts to encouraging all employees, including those working around the world, to deepen their understanding about glaucoma.

* Rehabilitation makeup: Makeup for nullifying a defect or helping return to the original condition
About Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a nearly 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. The company's Chairman and CEO is Akira Kurokawa. For more information, please visit Santen's website (

Source: Santen Pharmaceutical Co., Ltd.
AsiaNet 77256

Latest Press Release

Biotech Conagen Acquires Production Platform of Therapeutic Proteins

Conagen, a vertically integrated synthetic biology company located in Boston's biotech corridor, announced today that it has acquired a fermentation-based technology for the production of therapeutically useful glycoproteins. The acquisition includes...

Pneuma Respiratory, Inc. Announces New Chairman of the Board

Pneuma Respiratory, Inc. announced that Board member Jay Morgan has assumed the position of Chairman of the Board. Pneuma's previous Chairman, Walt Robb, will remain a member of the Board of Directors. Jay Morgan served as VP Global Innovation and...

Global market of dietary supplement is welcoming a rising star GLYMATE

Glymate(TM), a newly founded nutraceutical company in Southern California. Its proprietary sugar balance dietary supplement was officially announced in the United States in June 2019, marking the official launch of the global marketing of this product,...

Xinhua Silk Road: Tasly remains China#s 2019 National Tech Innovation Demonstration Enterprise

Tasly Holding Group, one of China's leading pharmaceuticals companies, has recently passed through the country's review of National Technology Innovation Demonstration Enterprise in 2019, thanks to its continuous innovations made in the recent...

SweeGen#s non-GMO Reb M Stevia Leaf Sweetener Approved in Singapore

SweeGen, Inc., a nature-based sweetener company, announced the Singapore Food Agency has added SweeGen's Reb M Stevia Leaf Sweetener to the list of permitted food additives. SweeGen's Reb M is a non-caloric stevia sweetener that provides sweetness with...

Related Topics